Skip to main navigation Skip to search Skip to main content

Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi

  • Martine Keenan
  • , Paul W. Alexander
  • , Hugo Diao
  • , Wayne M. Best
  • , Andrea Khong
  • , Maria Kerfoot
  • , R. C.Andrew Thompson
  • , Karen L. White
  • , David M. Shackleford
  • , Eileen Ryan
  • , Alison D. Gregg
  • , Susan A. Charman
  • , Thomas W. Von Geldern
  • , Ivan Scandale
  • , Eric Chatelain
  • Epichem Pty Ltd
  • Murdoch University
  • Monash University
  • Drugs for Neglected Diseases initiative (DNDi)

Research output: Contribution to journalArticlepeer-review

Abstract

A scaffold hopping exercise undertaken to expand the structural diversity of the fenarimol series of anti-Trypanosoma cruzi (T. cruzi) compounds led to preparation of simple 1-[phenyl(pyridin-3-yl)methyl]piperazinyl analogues of fenarimol which were investigated for their ability to inhibit T. cruzi in vitro in a whole organism assay. A range of compounds bearing amide, sulfonamide, carbamate/carbonate and aryl moieties exhibited low nM activities and two analogues were further studied for in vivo efficacy in a mouse model of T. cruzi infection. One compound, the citrate salt of 37, was efficacious in a mouse model of acute T. cruzi infection after once daily oral dosing at 20, 50 and 100 mg/kg for 5 days.

Original languageEnglish
Pages (from-to)1756-1763
Number of pages8
JournalBioorganic and Medicinal Chemistry
Volume21
Issue number7
DOIs
Publication statusPublished - 1 Apr 2013
Externally publishedYes

Keywords

  • Chagas disease
  • Fenarimol
  • Inhibition
  • Trypanosoma cruzi

Fingerprint

Dive into the research topics of 'Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi'. Together they form a unique fingerprint.

Cite this